173 related articles for article (PubMed ID: 31846800)
1. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.
Guo S; Fesler A; Huang W; Wang Y; Yang J; Wang X; Zheng Y; Hwang GR; Wang H; Ju J
Mol Ther Nucleic Acids; 2020 Mar; 19():228-239. PubMed ID: 31846800
[TBL] [Abstract][Full Text] [Related]
2. Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma.
Yuen JG; Hwang GR; Fesler A; Intriago E; Pal A; Ojha A; Ju J
Mol Ther Oncol; 2024 Mar; 32(1):200769. PubMed ID: 38596306
[TBL] [Abstract][Full Text] [Related]
3. Development of Gemcitabine-Modified miRNA Mimics as Cancer Therapeutics for Pancreatic Ductal Adenocarcinoma.
Yuen JG; Hwang GR; Fesler A; Intriago E; Pal A; Ojha A; Ju J
bioRxiv; 2023 Aug; ():. PubMed ID: 37645827
[TBL] [Abstract][Full Text] [Related]
4. Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1.
Fesler A; Liu H; Ju J
Oncotarget; 2018 Jan; 9(2):2367-2383. PubMed ID: 29416778
[TBL] [Abstract][Full Text] [Related]
5. 5-FU-miR-15a Inhibits Activation of Pancreatic Stellate Cells by Reducing YAP1 and BCL-2 Levels In Vitro.
Almanzar VMD; Shah K; LaComb JF; Mojumdar A; Patel HR; Cheung J; Tang M; Ju J; Bialkowska AB
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835366
[TBL] [Abstract][Full Text] [Related]
6. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression.
Guo S; Xu X; Tang Y; Zhang C; Li J; Ouyang Y; Ju J; Bie P; Wang H
Cancer Lett; 2014 Mar; 344(1):40-46. PubMed ID: 24252251
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
[TBL] [Abstract][Full Text] [Related]
8. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
10. Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinoma.
Rampioni Vinciguerra GL; Capece M; Reggiani Bonetti L; Nigita G; Calore F; Rentsch S; Magistri P; Ballarin R; Di Benedetto F; Distefano R; Cirombella R; Vecchione A; Belletti B; Baldassarre G; Lovat F; Croce CM
Signal Transduct Target Ther; 2024 Feb; 9(1):31. PubMed ID: 38342897
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
Zhou L; Zhang WG; Wang DS; Tao KS; Song WJ; Dou KF
Oncol Rep; 2014 Oct; 32(4):1734-40. PubMed ID: 25109303
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms.
Long LM; Zhan JK; Wang HQ; Li S; Chen YY; Liu YS
Pathobiology; 2017; 84(1):38-48. PubMed ID: 27458977
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of miR-15a and miR-214 in human pancreatic cancer.
Zhang XJ; Ye H; Zeng CW; He B; Zhang H; Chen YQ
J Hematol Oncol; 2010 Nov; 3():46. PubMed ID: 21106054
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.
Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L
J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254
[TBL] [Abstract][Full Text] [Related]
17. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.
Fukuhisa H; Seki N; Idichi T; Kurahara H; Yamada Y; Toda H; Kita Y; Kawasaki Y; Tanoue K; Mataki Y; Maemura K; Natsugoe S
J Hum Genet; 2019 Jun; 64(6):521-534. PubMed ID: 30858505
[TBL] [Abstract][Full Text] [Related]
18. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma.
Zhao C; Zhang J; Zhang S; Yu D; Chen Y; Liu Q; Shi M; Ni C; Zhu M
Oncol Rep; 2013 Jul; 30(1):276-84. PubMed ID: 23612862
[TBL] [Abstract][Full Text] [Related]
20. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
Hartman SJ; Bagby SM; Yacob BW; Simmons DM; MacBeth M; Lieu CH; Davis SL; Leal AD; Tentler JJ; Diamond JR; Eckhardt SG; Messersmith WA; Pitts TM
Front Oncol; 2021; 11():642328. PubMed ID: 33869031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
